JP2006199626A - Composition for ameliorating dermal function containing ceramide of acetic acid bacterium - Google Patents
Composition for ameliorating dermal function containing ceramide of acetic acid bacterium Download PDFInfo
- Publication number
- JP2006199626A JP2006199626A JP2005013382A JP2005013382A JP2006199626A JP 2006199626 A JP2006199626 A JP 2006199626A JP 2005013382 A JP2005013382 A JP 2005013382A JP 2005013382 A JP2005013382 A JP 2005013382A JP 2006199626 A JP2006199626 A JP 2006199626A
- Authority
- JP
- Japan
- Prior art keywords
- acetic acid
- ceramide
- composition
- acid bacteria
- skin function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 title claims abstract description 343
- 229940106189 ceramide Drugs 0.000 title claims abstract description 99
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 title claims abstract description 93
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 title claims abstract description 93
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 title claims abstract description 93
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 title claims abstract description 92
- 241000894006 Bacteria Species 0.000 title claims abstract description 65
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 230000004215 skin function Effects 0.000 title claims abstract description 31
- 239000002798 polar solvent Substances 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 235000013305 food Nutrition 0.000 claims description 13
- 235000021419 vinegar Nutrition 0.000 claims description 13
- 239000000052 vinegar Substances 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 230000000813 microbial effect Effects 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000013592 cell lysate Substances 0.000 claims 1
- 229960000583 acetic acid Drugs 0.000 abstract description 106
- 230000000694 effects Effects 0.000 abstract description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 17
- 230000037303 wrinkles Effects 0.000 abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 14
- 230000002265 prevention Effects 0.000 abstract description 9
- 239000002904 solvent Substances 0.000 abstract description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract description 6
- 150000002576 ketones Chemical class 0.000 abstract description 6
- 239000012046 mixed solvent Substances 0.000 abstract description 3
- 239000012362 glacial acetic acid Substances 0.000 abstract description 2
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 235000011054 acetic acid Nutrition 0.000 description 99
- 210000003491 skin Anatomy 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 25
- 239000000047 product Substances 0.000 description 15
- 230000003020 moisturizing effect Effects 0.000 description 13
- -1 sterol lipid Chemical class 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 230000001153 anti-wrinkle effect Effects 0.000 description 12
- 239000002537 cosmetic Substances 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 10
- 241000589220 Acetobacter Species 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 230000037406 food intake Effects 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 235000015110 jellies Nutrition 0.000 description 4
- 239000008274 jelly Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 125000002657 sphingoid group Chemical group 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 244000283763 Acetobacter aceti Species 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 241000589236 Gluconobacter Species 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 235000010716 Vigna mungo Nutrition 0.000 description 3
- 240000001417 Vigna umbellata Species 0.000 description 3
- 235000011453 Vigna umbellata Nutrition 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 150000001783 ceramides Chemical class 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- SYBYTAAJFKOIEJ-UHFFFAOYSA-N 3-Methylbutan-2-one Chemical compound CC(C)C(C)=O SYBYTAAJFKOIEJ-UHFFFAOYSA-N 0.000 description 2
- 235000007847 Acetobacter aceti Nutrition 0.000 description 2
- 241001497543 Acetobacter indonesiensis Species 0.000 description 2
- 241001497546 Acetobacter lovaniensis Species 0.000 description 2
- 241000589212 Acetobacter pasteurianus Species 0.000 description 2
- 241000923672 Acetobacter pomorum Species 0.000 description 2
- 241001497552 Acetobacter tropicalis Species 0.000 description 2
- 241000589210 Acidomonas methanolica Species 0.000 description 2
- 241000308412 Asaia bogorensis Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 241000032681 Gluconacetobacter Species 0.000 description 2
- 241001518248 Gluconobacter cerinus Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000589216 Komagataeibacter hansenii Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241000736131 Sphingomonas Species 0.000 description 2
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229920000249 biocompatible polymer Polymers 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- XNLICIUVMPYHGG-UHFFFAOYSA-N pentan-2-one Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 230000037330 wrinkle prevention Effects 0.000 description 2
- RTQVJTLVVBJRJG-UHFFFAOYSA-N (2S,3R,4E,8E)-4,8-sphingadienine Natural products CCCCCCCCCC=CCCC=CC(O)C(N)CO RTQVJTLVVBJRJG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- PTTPXKJBFFKCEK-UHFFFAOYSA-N 2-Methyl-4-heptanone Chemical compound CC(C)CC(=O)CC(C)C PTTPXKJBFFKCEK-UHFFFAOYSA-N 0.000 description 1
- QQZOPKMRPOGIEB-UHFFFAOYSA-N 2-Oxohexane Chemical compound CCCCC(C)=O QQZOPKMRPOGIEB-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 241001310537 Acetobacter orientalis Species 0.000 description 1
- 241001478307 Acidomonas Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 240000001733 Altingia excelsa Species 0.000 description 1
- 241000308413 Asaia Species 0.000 description 1
- 241000355090 Asaia bogorensis NBRC 16594 Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- VDRZDTXJMRRVMF-UONOGXRCSA-N D-erythro-sphingosine Natural products CCCCCCCCCC=C[C@@H](O)[C@@H](N)CO VDRZDTXJMRRVMF-UONOGXRCSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 244000054626 Gastrochilus intermedius Species 0.000 description 1
- 241001468096 Gluconacetobacter diazotrophicus Species 0.000 description 1
- 241000423296 Gluconacetobacter diazotrophicus PA1 5 Species 0.000 description 1
- 241000320577 Gluconacetobacter sacchari Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 241001602876 Nata Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- MIUIRGGKIICMBP-NFOZDHADSA-N [27-oxo-27-[[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]amino]heptacosyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC MIUIRGGKIICMBP-NFOZDHADSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940048864 ceramide 1 Drugs 0.000 description 1
- 125000001549 ceramide group Chemical group 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 150000002313 glycerolipids Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000005368 silicate glass Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- RTQVJTLVVBJRJG-SEXYCKHXSA-N sphinga-4E,8E-dienine Chemical compound CCCCCCCCC\C=C\CC\C=C\[C@@H](O)[C@@H](N)CO RTQVJTLVVBJRJG-SEXYCKHXSA-N 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000005068 transpiration Effects 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 150000008498 β-D-glucosides Chemical class 0.000 description 1
Images
Abstract
Description
本発明は、経口摂取により、保湿、肌荒れ防止改善、シワ防止改善等の美容効果を有する肌機能改善用組成物に関するものである。 The present invention relates to a composition for improving skin function, which has cosmetic effects such as moisturizing, improvement of rough skin prevention, improvement of prevention of wrinkles, etc. by oral ingestion.
植物由来のセラミドは、人間の皮膚器官の構成成分であり、経口摂取により保湿、肌荒れ防止改善、シワ防止改善等の美容効果があることが知られている(例えば、非特許文献1及び非特許文献2参照)。
Plant-derived ceramide is a component of human skin organs and is known to have cosmetic effects such as moisturizing, preventing rough skin, and preventing wrinkles by oral ingestion (for example, Non-Patent
セラミドは、脂肪、グリセロ脂質、及びステロール脂質を除く脂質を指すものであって、セラミドには、上記したように小麦、米、ダイズ等の植物より抽出したもの、牛脳などの動物から抽出したもの、酵母などの真核微生物や、スフィンゴモナスなどの原核微生物から抽出したものがある。しかし、BSE問題などにより牛脳などの動物由来のセラミドは経口摂取することは敬遠される傾向があり、また、その食経験がないことよりスフィンゴモナスなどの微生物は経口摂取が敬遠されている。 Ceramide refers to lipids excluding fat, glycerolipid, and sterol lipid. Ceramide is extracted from plants such as wheat, rice and soybean as described above, and extracted from animals such as cow brain. And eukaryotic microorganisms such as yeast and those extracted from prokaryotic microorganisms such as Sphingomonas. However, ceramides derived from animals such as bovine brain tend to be avoided due to BSE problems, and microorganisms such as Sphingomonas are avoided from oral intake due to their lack of dietary experience.
従って、経口摂取によって、保湿、肌荒れ防止改善、シワ防止改善等の美容効果を期待する場合は、小麦、米、ダイズ等の植物から抽出されたセラミドが利用されていた。 Therefore, ceramides extracted from plants such as wheat, rice, and soybean have been used when expecting beauty effects such as moisturizing, preventing rough skin, and preventing wrinkles by oral ingestion.
しかしながら、小麦、米、ダイズ等の植物から抽出されたセラミドを経口摂取した場合は、その効果は十分なものではなく、より効果の強いものが求められていた。 However, when ceramide extracted from plants such as wheat, rice, and soybean is orally ingested, the effect is not sufficient, and a more effective one has been demanded.
本発明は、酢酸菌由来のセラミドを有効成分とすることを特徴とする肌機能改善組成物に関するものであるが、酢酸菌セラミドにおいて、植物セラミドを越えたきわめて顕著な美容効果があること、しかもその効果が経口摂取によって奏されることは、従来知られておらず、新規である。
本発明の目的は、植物セラミドよりも効果が高く、経口摂取することにより、保湿、肌荒れ防止改善、シワ防止改善等の効果を有する肌機能改善用組成物を提供することにある。 The object of the present invention is to provide a composition for improving skin function, which is more effective than plant ceramide and has effects such as moisturizing, improvement of rough skin prevention, improvement of prevention of wrinkles, etc. when taken orally.
本発明者らは、醸造酢製造菌として古来より使用されており、安全性の高いことが認知されている酢酸菌に着目した。 The present inventors have focused on acetic acid bacteria that have been used since ancient times as brewing vinegar-producing bacteria and are recognized to be highly safe.
そして、本発明者らは、醸造酢の生産に用いられている酢酸菌から抽出した酢酸菌セラミドを経口摂取することにより、保湿、肌荒れ防止改善、シワ防止改善等の美容効果があることを見出し、本発明を完成させた。 And the present inventors have found that by ingesting acetic acid bacteria ceramide extracted from acetic acid bacteria used for the production of brewed vinegar, there are cosmetic effects such as moisturizing, improvement of rough skin prevention, improvement of wrinkle prevention, etc. The present invention has been completed.
すなわち、請求項1に記載の本発明は、酢酸菌セラミドを有効成分として含有することを特徴とする肌機能改善用組成物に関する。
また、請求項2に記載の本発明は、酢酸菌セラミドを含有する酢酸菌の細胞破砕物を有効成分として含有することを特徴とする肌機能改善用組成物に関する。
さらに、請求項3に記載の本発明は、酢酸菌セラミドが酢酸菌から極性溶媒を用いて抽出されたものであることを特徴とする請求項1に記載の肌機能改善用組成物に関する。
また、請求項4に記載の本発明は、飲食品であることを特徴とする請求項1〜請求項3に記載の肌機能改善用組成物に関する。
そして、請求項5に記載の本発明は、飲食品が食酢であることを特徴とする請求項4に記載の肌機能改善用組成物に閲する。
That is, the present invention according to
Moreover, this invention of
Furthermore, the present invention described in
Moreover, this invention of
And this invention of Claim 5 reviews the composition for skin function improvement of
本発明の酢酸菌セラミドを含有した肌機能改善組成物は、直接、酢酸菌セラミドを経口摂取することにより保湿、肌荒れ防止改善、シワ防止改善等の美容効果がある。また、酢酸菌セラミドを含有する酢酸菌の細胞破壊物又は酢酸菌の極性溶媒抽出物を有効成分として含有させても、同様の肌機能改善効果が得られる。 The skin function improving composition containing acetic acid ceramide of the present invention has cosmetic effects such as moisturizing, preventing rough skin, and preventing wrinkle by directly ingesting acetic acid ceramide. The same skin function improving effect can be obtained even if a cell destruction product of acetic acid bacteria containing acetic acid bacteria ceramide or a polar solvent extract of acetic acid bacteria is contained as an active ingredient.
以下、本発明を詳細に説明する。 Hereinafter, the present invention will be described in detail.
本発明で用いる酢酸菌セラミドは、ヒト型セラミドのスフィンゴイド塩基部分のスフィンゴシンの前駆体であるスフィンガニンと脂肪酸がアミド結合した構造を有しており、例えば次のようにして得ることができる。 The acetic acid bacteria ceramide used in the present invention has a structure in which a sphingine precursor, a sphingosine precursor of sphingoid base moiety of human ceramide, and a fatty acid are amide-bonded, and can be obtained, for example, as follows.
例えば、酢酸菌を原料として、極性溶媒を用いて抽出し、これを酢酸菌セラミドとして使用してもよいし、得られた抽出物を更に有機溶媒で再結晶させてもよい。 For example, acetic acid bacteria may be used as a raw material and extracted using a polar solvent, and this may be used as acetic acid bacteria ceramide, or the obtained extract may be further recrystallized with an organic solvent.
有機溶媒としては、アルコール、脂肪族カルボン酸エステル、ケトン等、有機溶剤であればすべてのものが、単用又は2種以上併用される。アルコールとしては、メタノール、エタノール、プロパノール、イソプロパノール、ブタノール等各種低級アルコールが例示され、脂肪族カルボン酸エステルとしては、ギ酸、酢酸、プロピオン酸、酪酸、吉草酸、カプロン酸等の分枝又は直鎖の飽和脂肪酸のほか、各種の不飽和脂肪酸のアルコールエステル、例えば上記アルコールのエステルが例示される。 As the organic solvent, all organic solvents such as alcohol, aliphatic carboxylic acid ester and ketone can be used alone or in combination of two or more. Examples of the alcohol include various lower alcohols such as methanol, ethanol, propanol, isopropanol, and butanol. Examples of the aliphatic carboxylic acid ester include branched or straight chain such as formic acid, acetic acid, propionic acid, butyric acid, valeric acid, and caproic acid. In addition to the saturated fatty acids, alcohol esters of various unsaturated fatty acids, for example, esters of the above alcohols are exemplified.
ケトンとしては、アセトン、エチルメチルケトン、メチルプロピルケトン、イソプロピルメチルケトン、ブチルメチルケトン、イソブチルケトン等が例示される。 Examples of the ketone include acetone, ethyl methyl ketone, methyl propyl ketone, isopropyl methyl ketone, butyl methyl ketone, and isobutyl ketone.
酢酸菌セラミドの抽出に使用する極性溶媒としては、水、グリセリン、アルコール、ケトン、氷酢酸など極性溶媒であればすべてのものが単用又は2種以上併用することができる。アルコール、ケトンとしては、上記に例示したものが適宜使用可能である。 As the polar solvent used for the extraction of acetic acid ceramide, all polar solvents such as water, glycerin, alcohol, ketone, glacial acetic acid can be used alone or in combination of two or more. As alcohol and ketone, those exemplified above can be used as appropriate.
酢酸菌体から、極性溶媒を用いて酢酸菌セラミドを抽出するには、例えば、酢酸菌菌体自体、又は酢酸菌菌体を適当に超音波等で破砕した後、極性溶媒で酢酸菌セラミドを抽出し、得られた抽出液はそのまま酢酸菌セラミドとして使用することができる。 In order to extract acetic acid bacteria ceramide from acetic acid bacteria using a polar solvent, for example, acetic acid bacteria or the acetic acid bacteria are appropriately crushed with ultrasonic waves, and then acetic acid ceramide is extracted with a polar solvent. The extracted liquid obtained after extraction can be used as it is as acetic acid ceramide.
抽出は、湿潤菌体又は乾燥菌体と溶剤とを充分に接触させて行なえばよく、常法が適宜適用される。例えば、乾燥菌体の場合、有機溶剤(必要あれば、その0.1〜10倍、通常はそれと同量程度の水を加え)を菌体1kgに対して0.5〜30リットル、通常は5〜15リットル程度加え、よく混合した後、遠心分離や濾過等の分離処理を行って上層を回収したり、あるいは、ソックスレー抽出器を用いて、乾燥菌体10kgに対して上記と同量のアルコール等の有機溶剤を加えて加熱還流し、得られた抽出液を減圧乾固した後、0.5〜15リットル程度、通常は2〜8リットルのケトン類等の有機溶剤を加えて溶解し、沈澱物を分離した後の濾液(上清)を抽出液として回収すればよい。 The extraction may be performed by sufficiently bringing wet or dry cells into contact with a solvent, and conventional methods are appropriately applied. For example, in the case of dry cells, 0.5 to 30 liters of organic solvent (if necessary, 0.1 to 10 times, usually adding the same amount of water) to 1 kg of cells, usually Add about 5-15 liters, mix well, then perform separation treatment such as centrifugation or filtration to recover the upper layer, or use a Soxhlet extractor to produce 10 kg of dry cells with the same amount as above. After adding an organic solvent such as alcohol and heating to reflux, the resulting extract is dried under reduced pressure, and then dissolved by adding 0.5 to 15 liters, usually 2 to 8 liters of an organic solvent such as ketones. The filtrate (supernatant) after separating the precipitate may be recovered as an extract.
また、溶媒(例えば、クロロホルム、アルコール、水の混液)を用いて抽出した後、下層を脂質粗画分として回収し、これに苛性ソーダや苛性カリその他のアルカリ溶液を加えて弱アルカリ分解し、アルカリ安定脂質を得、これを酢酸菌セラミドとしてよい。更に所望する場合、これをシリカゲルカラムクロマトグラフィー等で処理し、例えば、クロロホルム、酢酸の混合溶媒で洗浄した後、クロロホルム、アルコールの混合溶媒で溶出される画分を酢酸菌セラミドとして使用してもよい。 In addition, after extraction using a solvent (for example, a mixture of chloroform, alcohol, and water), the lower layer is recovered as a crude lipid fraction, and caustic soda, caustic potash, and other alkaline solutions are added to weakly decompose the alkali to stabilize the alkali. Lipid is obtained, which may be acetic acid ceramide. Further, if desired, this may be treated with silica gel column chromatography or the like. For example, after washing with a mixed solvent of chloroform and acetic acid, the fraction eluted with the mixed solvent of chloroform and alcohol may be used as ceramide of acetic acid bacteria. Good.
このようにして得られた抽出液は、そのまま、酢酸菌セラミドとして使用することができるが、更に、抽出液の処理物も使用することができ、処理物としては例えば、抽出液の濃縮物、ペースト化物、乾燥物、希釈物が使用できるほか、精製物、例えば、液体クロマトグラフィーや向流分配法などで酢酸菌セラミドを分離精製し、またそれを採取して、酢酸菌セラミドとして用いることもできる。なお、本発明において、酢酸菌セラミドには、精製物のほか、粗精製物や含有物も包含され、これらの処理物も含まれる。 The extract thus obtained can be used as it is as acetic acid bacteria ceramide, but further, a processed product of the extract can also be used. Examples of the processed product include a concentrate of the extract, Pasted products, dried products and diluted products can be used, and purified products such as acetic acid ceramides can be separated and purified by liquid chromatography, countercurrent distribution, etc., and collected and used as acetic acid ceramides. it can. In the present invention, acetic acid ceramide includes not only purified products but also crude products and contained products, and these treated products are also included.
また、酢酸菌セラミドは、酢酸菌体、特にその細胞膜に存在するので、抽出工程を経ることなく酢酸菌をそのまま酢酸菌セラミドとして使用したり、含有させたりしてもよい。更にまた、体内での吸収を考慮して、高圧ホモジナイザー、フレンチプレスなど高圧式破砕機や、超音波式破砕機を用いて細胞破壊したものをそのまま酢酸菌セラミドとして使用したり、含有させたりしてもよい。酢酸菌の破砕処理は、上記のほか、常法によって適宜実施することができる。 In addition, since acetic acid bacteria ceramide is present in acetic acid bacteria, particularly in the cell membrane thereof, the acetic acid bacteria may be used as it is as acetic acid bacteria ceramide or may be contained without passing through the extraction step. Furthermore, taking into account absorption in the body, high-pressure crushers such as high-pressure homogenizers and French presses, and cells that have been disrupted using an ultrasonic crusher can be used as acetic acid ceramides as they are. May be. In addition to the above, the crushing treatment of acetic acid bacteria can be appropriately performed by a conventional method.
酢酸菌体破砕物の場合も抽出物と同様であって、酢酸菌を破砕して(通常、湿菌体に0.5〜2倍量の水を加えた後に破砕処理する)得られた破砕物をそのまま酢酸菌セラミドとして使用できるほか、上記と同様に処理して得た各種処理物も酢酸菌セラミドとして使用することができる。 In the case of acetic acid cell disruption product, it is the same as the extract, and the disruption obtained by crushing acetic acid bacteria (usually crushing after adding 0.5 to 2 times the amount of water to the wet cell) The product can be used as an acetic acid ceramide as it is, and various processed products obtained by treating in the same manner as described above can also be used as an acetic acid ceramide.
本発明において用いられる酢酸菌としては、特に制限はなく、例えば、グルコンアセトバクター属(Gluconacetobacter)、グルコノバクター属(Gluconobacter)、アセトバクター属(Acetobacter)、アサイア属(Asaia)またはアシドモナス属(Acidomonas)に属する酢酸菌が例示される。 The acetic acid bacterium used in the present invention is not particularly limited. Acetobacteria belonging to) are exemplified.
さらに詳細には、グルコンアセトバクター属(Gluconacetobacter)の酢酸菌としては、グルコンアセトバクター・ハンゼニイ(Gluconacetobacter hansenii)、グルコンアセトバクター・ジアゾトロフィカス(Gluconacetobacter diazotrophicus)、グルコンアセトバクター・インタメデイウス(Gluconacetobacter intermedius)、グルコンアセトバクター・サッカリ(Gluconacetobacter sacchari)などが例示される。 More specifically, examples of acetic acid bacteria of the genus Gluconacetobacter include Gluconacetobacter hansenii, Gluconacetobacter diazotrophicus, Gluconacetobacter diterotropicus ), Gluconacetobacter sacchari and the like.
また、グルコノバクター属(Gluconobacter)としては、グルコノバクター・フラトウリ(Gluconobacter frateurii)、グルコノバクター・セリナス(Gluconobacter cerinus)などが例示される。 Examples of the genus Gluconobacter include Gluconobacter freatorii and Gluconobacter cerinus.
さらに、アセトバクター属(Acetobacter)の酢酸菌としては、アセトバクター・トロピカリス(Acetobacter tropicalis)、アセトバクター・インドネシエンシス(Acetobacter indonesiensis)、アセトバクター・シジギイ(Acetobacter syzygii)、アセトバクター・シビノンゲンシス(Acetobacter cibinongensis)、アセトバクター・オリエンタリス(Acetobacter orientalis)、アセトバクター・パスツリアヌス(Acetobacter pasteurianus)、アセトバクター・オルレアネンシス(Acetobacter orleanensis)、アセトバクター・ロバニエンシス(Acetobacter lovaniensis)、アセトバクター・アセチ(Acetobacter aceti)、アセトバクター・ポモラム(Acetobacter pomorum)などが例示される。 Furthermore, the acetic acid bacteria of the genus Acetobacter (Acetobacter tropicalis), Acetobacter indonesiensis, Acetobacter siggi cis (B) ), Acetobacter orientalis, Acetobacter pasteurianus, Acetobacter orenenensis, Acetobacter orenensis Acetobacter lovaniensis), Acetobacter aceti (Acetobacter aceti), such as Acetobacter Pomoramu (Acetobacter pomorum) are exemplified.
さらに、アサイア属(Asaia)の酢酸菌としては、アサイア・ボゴレンシス(Asaia bogorensis)、アサイア・シアメンシス(Asaia siamensis)などが例示される。 Furthermore, as acetic acid bacteria of the genus Asia (Asia), Asaia bogorensis (Asaia bogorensis), Asaia siemensis (Asiaia siemensis), etc. are illustrated.
また、アシドモナス属(Acidomonas)の酢酸菌は、アシドモナス・メタノリカ(Acidomonas methanolica)などが例示される。 Examples of the acetic acid bacteria belonging to the genus Acidomonas include Acidomonas methanolica.
酢酸菌としては、上記のほか、寄託菌、市販菌、食酢や種酢に含有されている酢酸菌等も適宜使用可能である。寄託菌としては次のものが非限定的に例示される。 As the acetic acid bacteria, in addition to the above, deposited bacteria, commercially available bacteria, acetic acid bacteria contained in vinegar and seed vinegar, and the like can be used as appropriate. Non-limiting examples of deposited bacteria are as follows.
アセトバクター・トロピカリス(Acetobacter tropicalis) NBRC 16470、同インドネシエンシス(A.indonesiensis) NBRC 16471、同シジギイ(A.syzygii) NBRC 16604、同シビノンゲンシス(A.cibinongensis) NBRC 16605、同オリエンタリス(A.orientalis) NBRC 16606、同パスツリアヌス(A.pasteurianus) DSM 3509、同オルレアネンシス(A.orleanensis) NBRC 13752、同ロバニエンシス(A.lovaniensis) NBRC 13753、同アセチ(A.aceti)NBRC 14818、同ポモラム(A.pomorum) DSM 11825など。 Acetobacter tropicalis NBRC 16470, A. indonesiensis NBRC 16471, A. sygigi NBRC 16604, S.B. Cis. NBRC 16606, A. pasteurianus DSM 3509, A. orleenensis NBRC 13752, A. lovaniensis NBRC 13753, A. aceti NBRC, A. pomorum) DSM 1 1825 etc.
グルコンアセトバクター・ハンゼニイ(Gluconacetobacter hansenii) NBRC 14820、同ジアゾトロフィカス(Ga.diazotrophicus) DSM 5601、同インタメデイウス(Ga.intermedius) DSM 11804、同サッカリ(Ga.sacchari) DSM 12717など、
グルコノバクター・フラトウリ(Gluconobacter frateurii) NBRC 3264、同セリナス(G.cerinus) NBRC 3267など、
アサイア・ボゴレンシス(Asaia bogorensis) NBRC 16594、同シアメンシス(A.siamensis) NBRC 16457など、
アシドモナス・メタノリカ(Acidomonas methanolica) DSM 5432など。
Gluconacetobacter hansenii NBRC 14820, G. diazotrophicus DSM 5601, G. intermedius DSM 11804, G. sacchar 27
Gluconobacter freatorii NBRC 3264, G. cerinus NBRC 3267, etc.
Asaia Bogorensis NBRC 16594, A. siamensis NBRC 16457, etc.
Acidomonas methanolica DSM 5432 and the like.
これらの酢酸菌は酢酸発酵に用いられ、大量に増殖する。なお、酢酸菌は、ナタデココ、カスピ海ヨーグルト、紅茶きのこなどで食経験があり、また、食酢発酵においては発酵後に廃棄されており安価に入手することができる。 These acetic acid bacteria are used for acetic acid fermentation and grow in large quantities. In addition, acetic acid bacteria have a food experience in Nata de coco, Caspian sea yogurt, black tea mushrooms, etc. Moreover, in vinegar fermentation, it is discarded after fermentation and can be obtained at low cost.
本発明に係る酢酸菌セラミドを含有する肌機能改善組成物の形態としては、錠剤、カプセル剤、粉末剤、液剤、顆粒剤、散剤等の剤形に製剤化したものが例示され、例えば、医薬品、経口化粧品、サプリメント等として使用することができる。さらに、飲食品の形態としては、具体的には、キャンデイ、ガム、ゼリー等の菓子、食パン、米飯等の主食品、アルコール飲料、牛乳、食酢飲料等の飲料等の飲料、また、醤油、味噌、食酢等の調味料等が挙げられる。 Examples of the form of the skin function improving composition containing acetic acid ceramide according to the present invention include those formulated into dosage forms such as tablets, capsules, powders, liquids, granules, powders, etc. It can be used as oral cosmetics, supplements and the like. Furthermore, as a form of food and drink, specifically, beverages such as sweets such as candy, gum and jelly, main foods such as bread and cooked rice, beverages such as alcoholic beverages, milk and vinegar beverages, soy sauce, miso And seasonings such as vinegar.
本発明において、食品中の酢酸菌セラミドの割合は、0.0001〜5重量%、好ましくは、0.001〜1重量%である。酢酸菌セラミドの添加量が0.0001重量%未満では、保湿、肌荒れ、シワ防止等の美容効果が発現しづらく、また、5重量%を越えると該組成物製造時の粘度が上昇し、また着色や香味の劣化がおこり、経口摂取に適さなくなるので好ましくない。 In the present invention, the proportion of acetic acid ceramide in the food is 0.0001 to 5% by weight, preferably 0.001 to 1% by weight. If the amount of acetic acid ceramide added is less than 0.0001% by weight, cosmetic effects such as moisturizing, rough skin, and prevention of wrinkles are difficult to develop, and if it exceeds 5% by weight, the viscosity during production of the composition increases. Coloring and flavor deterioration occur and are not suitable for oral intake.
本発明の肌機能改善用組成物としての酢酸菌セラミドの投与量は、成人1日当たり0.01mg〜1000mg、好ましくは0.1mg〜100mgである。成人1日当たり0.1mg未満の投与量では、保湿、肌荒れ防止改善、シワ防止改善等の美容効果が少なく、100mgを越えると消化吸収ができなくなる恐れがある。 The dosage of acetic acid ceramide as the skin function improving composition of the present invention is 0.01 mg to 1000 mg, preferably 0.1 mg to 100 mg per day for an adult. At doses of less than 0.1 mg per day for adults, there are few cosmetic effects such as moisturizing, improvement of rough skin prevention and improvement of wrinkle prevention, and if it exceeds 100 mg, digestion and absorption may not be possible.
本発明の肌機能改善用組成物は酢酸菌セラミドを有効成分として含有するが、それ以外の各種原料とを混合・均一化した後に、必要に応じて界面活性剤を混合して、安定化を図ることもできる。これらの界面活性剤としては、ソルビタン脂肪酸エステル、グリセリン脂肪酸エステル、プロピレングリコール脂肪酸エステル、ショ糖脂肪酸エステルおよびレシチンなどを用いることができる。 The composition for improving skin function of the present invention contains acetic acid ceramide as an active ingredient, and after mixing and homogenizing with other various raw materials, a surfactant is mixed as necessary to stabilize the composition. You can also plan. As these surfactants, sorbitan fatty acid ester, glycerin fatty acid ester, propylene glycol fatty acid ester, sucrose fatty acid ester, lecithin and the like can be used.
また、本発明によれば、食酢その他酢酸菌含有飲食品を破砕処理したり、酢酸菌を飲食品に添加した後これを破砕処理したり、酢酸菌の破砕処理物(その処理物も含む、以下同じ)を飲食品に添加したり、酢酸菌体又はその破砕処理物の溶剤抽出物(その処理物も含む、以下同じ)を飲食品に添加したりすることによって、肌機能改善組成物を製造することもできる。したがって、本発明は、これらの破砕処理物や飲食品は、肌機能改善のために経口摂取されるものである旨の表示を付した肌機能改善組成物を提供するものであって、調味や単なる飲用といった通常の用途に使用される食酢等の飲食品とは明確に区別されるものである。 In addition, according to the present invention, vinegar and other acetic acid bacteria-containing foods and beverages are crushed, or after adding acetic acid bacteria to food and drink, this is crushed, or acetic acid bacteria crushed products (including the treated products, The same applies hereinafter) to food and drink, or by adding a solvent extract of acetic acid bacterial cells or a crushed processed product thereof (including the processed product, the same shall apply hereinafter) to the food or drink. It can also be manufactured. Therefore, the present invention provides a skin function improving composition with an indication that these crushed processed foods and drinks are orally ingested for skin function improvement. It is clearly distinguished from foods and beverages such as vinegar used for ordinary uses such as mere drinking.
以下、本発明を実施例により更に説明するが、本発明は実施例のみに限定されるものではない。 EXAMPLES Hereinafter, although an Example demonstrates this invention further, this invention is not limited only to an Example.
(実施例1)
<ヒト皮膚器官培養を用いた酢酸菌セラミドの抗シワ活性>
酢酸菌セラミドの抗シワ活性を以下の要領で実施した。
Example 1
<Anti-wrinkle activity of acetic acid ceramide using human skin organ culture>
Anti-wrinkle activity of acetic acid ceramide was carried out as follows.
まず、酢酸菌セラミドは、以下の方法で調製した。すなわち、酢酸菌(Acetobacter aceti NBRC 14818)の100g乾燥菌体からクロロホルム−メタノール系の溶媒(グロロホルム:メタノール:水=1:1:0.8)5リットルで抽出し、その後、2層分離を行い、下層を脂質粗画分として回収した。次に、0.4N NaOHにより脂質粗画分を弱アルカリ分解し、アルカリ安定脂質を得た。 First, acetic acid bacteria ceramide was prepared by the following method. That is, 100 g dry cells of acetic acid bacteria (Acetobacter acetic NBRC 14818) were extracted with 5 liters of a chloroform-methanol solvent (groloform: methanol: water = 1: 1: 0.8) and then separated into two layers. The lower layer was recovered as a crude lipid fraction. Next, the crude lipid fraction was weakly alkali-degraded with 0.4N NaOH to obtain an alkali-stable lipid.
得られたアルカリ安定脂質を、クロロホルムで平衡化したシリカゲルカラムにかけ、クロロホルム:酢酸=100:1の溶媒で洗浄後、クロロホルム:メタノール=97:3の溶媒で溶出して得られた画分を乾固して、約0.5gの酢酸菌セラミドを得た。 The obtained alkali-stable lipid is applied to a silica gel column equilibrated with chloroform, washed with a solvent of chloroform: acetic acid = 100: 1, and eluted with a solvent of chloroform: methanol = 97: 3, and the fraction obtained is dried. Solidified to obtain about 0.5 g of acetic acid ceramide.
また、対照物として、ヒト型セラミド(Ceramide: Matreya社製)、及びヒト型糖セラミド(Ceramide β−D−glucoside from brain: Matreya社製)、植物型糖セラミド(Ceramide β−D−glucoside from plant: Matreya社製)を用いた。 As controls, human ceramide (Ceramide: manufactured by Matreya), human sugar ceramide (Ceramide β-D-glucoside from brain: manufactured by Matreya), and plant sugar ceramide (Ceramide β-D-glucoside fluoride) : Made by Matreya).
これらの試料を用い、下記の(1)〜(8)に示す抗シワ活性評価系により、酢酸菌セラミドの抗シワ活性を、改変ブロノフ拡散チャンバーを用いて、ヒト型糖セラミド、ヒト型セラミド、植物型糖セラミドと比較評価した。改変ブロノフ拡散チャンバーは、図1にその概略を示した。図中、PBSは生理食塩水、PG−biocompatible polymerはポリエチレングリコール−生物両立性ポリマー、Human skin sliceはヒト皮膚薄片、Culture mediumは培養液を、それぞれ示す。 Using these samples, the anti-wrinkle activity of acetic acid ceramide was evaluated using the modified Bronoff diffusion chamber according to the anti-wrinkle activity evaluation system shown in (1) to (8) below, and the human-type sugar ceramide, human-type ceramide, Comparative evaluation was made with plant-type sugar ceramide. The modified Bronov diffusion chamber is outlined in FIG. In the figure, PBS represents physiological saline, PG-biocompatible polymer represents polyethylene glycol-biocompatible polymer, Human skin slice represents human skin flakes, and Culture medium represents culture fluid.
(1)ヒト摘出皮膚片(インフォームドコンセント済み)を、改変ブロノフ拡散チャンバー(図1に概略を示した)に組込んだ。皮下側の培養液に本発明の酢酸菌セラミドならびに対照物を添加した。
(2)酢酸菌セラミドならびに対照物を添加後、2時間後に、皮膚片に紫外線A波(UV−A)を3J/cm2の強度で、1日当り2回照射した。なお、ランプと検体の間に珪酸ガラスを挟んだ。
(3)皮膚片を器官培養した。なお、培養基はDMEMab培地(+)10%FBS(ウシ胎児血清)を用いた。
(4)毎日同様な処理を行い、5〜10目間、器官培養を行った。
(5)器官培養終了跡、チャンバーから皮膚片を単離し、実体顕微鏡/CCDビデオカメラで皮膚表面を撮影し、皮膚表面写真を得た。
(6)その後、皮膚表面に対して、シリコンゴムでレプリカ作製を行い、そのレプリカの写真を撮影して、レプリカ写真を得た。
(7)上記(6)で作製したレプリカの表面凸凹形状をスキャンして、ラインヒストグラムを作成した。
(1) A human excised skin piece (with informed consent) was incorporated into a modified Bronov diffusion chamber (schematically shown in FIG. 1). The acetic acid ceramide of the present invention and a control substance were added to the culture medium on the subcutaneous side.
(2) Two hours after adding the acetic acid ceramide and the control substance, the skin pieces were irradiated with ultraviolet A waves (UV-A) at an intensity of 3 J /
(3) Organized skin pieces. As the culture medium, DMEMab medium (+) 10% FBS (fetal bovine serum) was used.
(4) The same treatment was performed every day, and organ culture was performed for 5 to 10 days.
(5) An organ culture trace, a skin piece was isolated from the chamber, and the skin surface was photographed with a stereomicroscope / CCD video camera to obtain a skin surface photograph.
(6) Thereafter, a replica was made with silicon rubber on the skin surface, and a photo of the replica was taken to obtain a replica photo.
(7) A line histogram was created by scanning the surface irregularities of the replica produced in (6) above.
(8)上記の(1)〜(7)の手順で皮膚表面写真、レプリカ写真、凸凹形状を投影したラインヒストグラムを元にして、抗シワ活性をPOOR、MEDIUM、GOOD、EXCELLENTの4段階に分けて評価した。なお、線状の皮溝が短く少数で規則的な場合は肌理(キメ)として認定しシワとは見なさなかった。また、広幅の皮溝で太くて長く陰影が濃い場合は、シワと認定した。なお、評価において、POORは劣る、MEDIUMは普通、GOODは良好、EXCELLENTは卓越している、をそれぞれ示す。 (8) The anti-wrinkle activity is divided into 4 stages of POOR, MEDIUM, GOOD, and EXCELLENT based on the skin surface photograph, replica photograph, and line histogram that projects the uneven shape in the procedure of (1) to (7) above. And evaluated. In addition, when the linear skin groove was short and regular, it was recognized as a texture and was not regarded as wrinkles. In addition, if the skin was wide and thick and long and the shadow was dark, it was recognized as a wrinkle. In the evaluation, POOR is inferior, MEDIUM is normal, GOOD is good, and EXCELLENT is excellent.
この抗シワ活性評価系は、体内で吸収した物質の皮膚への効果を見ることに優れており、真皮に分布する毛細血管を通してセラミドなどの有効成分が皮膚へ送達され、その結果、角質層セラミド/スクワレンによる細胞間質の保湿力増強、真皮での細胞外マトリックス構築促進、繊維芽細胞の増殖促進などの効能発現について調べるのに適している。 This anti-wrinkle activity evaluation system is excellent in seeing the effects of substances absorbed in the body on the skin, and active ingredients such as ceramide are delivered to the skin through capillaries distributed in the dermis, resulting in stratum corneum ceramide. / Squarene is suitable for investigating the effects of enhancing the moisturizing power of the cell stroma, promoting extracellular matrix construction in the dermis, and promoting fibroblast proliferation.
また、この皮膚片は4週間培養してもコラーゲン合成を95%以上維持しているので生存していることが実証されている。 In addition, it has been demonstrated that this skin piece survives because it maintains 95% or more of collagen synthesis even when cultured for 4 weeks.
そして、試験に供したヒト型糖セラミドはヒト型セラミドに糖が結合した物質であり、共にヒト生体内でその存在が確認されている。 The human-type ceramide used in the test is a substance in which a saccharide is bound to human-type ceramide, and both have been confirmed to exist in the human body.
また、植物糖セラミドは植物由来のセラミドが共通して有する構造でセラミド部分に糖が結合しているのを特徴として有し、今までにヒト生体内での存在は示されていない。それぞれの経口摂取したセラミドの一部はそのままの構造で吸収され作用すると考えられる。
上記の結果を表1に示した。
In addition, plant sugar ceramide has a structure that is common to plant-derived ceramides, and is characterized by saccharides bound to the ceramide moiety, and has not been shown to exist in human organisms so far. It is considered that a part of each ceramide taken orally is absorbed and acted as it is.
The results are shown in Table 1.
表1
――――――――――――――――――――――――――――――――――――――――
名称 評価 評価の根拠
――――――――――――――――――――――――――――――――――――――――
ヒト型糖セラミド EXCELLENT 肌理があって幅広や長いシワがない。
酢酸菌セラミド GOOD 広幅陥没がほぼ無い。細く短いシワが散見、総
じて平滑である。
ヒト型セラミド MEDIUM 皮膚表面は皮丘が僅かに存在する程度でシワ
が殆どないが、表面レプリカでは広幅で陰影
の濃い皮溝が目立つ。
植物型糖セラミド MEDIUM 幅広で長いシワが見られる。
無投与区 POOR 随所に広幅の陥没部が認められる。
――――――――――――――――――――――――――――――――――――――――
Table 1
――――――――――――――――――――――――――――――――――――――――
Name Evaluation Basis for evaluation ――――――――――――――――――――――――――――――――――――――――
Human sugar ceramide EXCELLENT There is a texture and there are no wide or long wrinkles.
Acetic acid ceramide GOOD There is almost no wide depression. Thin and short wrinkles are scattered, total
Smooth.
Human-type ceramide MEDIUM The skin surface is wrinkled to the extent that there are a few cuticles.
There is almost no, but the surface replica is wide and shaded
The thick skin groove is conspicuous.
Plant-type sugar ceramide MEDIUM Wide and long wrinkles can be seen.
Non-administration zone POOR Wide depressions are observed everywhere.
――――――――――――――――――――――――――――――――――――――――
表1に示したように、酢酸菌セラミドは植物型糖セラミドよりも優れた抗シワ活性を有し、このことより酢酸菌セラミドは経口摂取により保湿、肌荒れ防止改善、シワ防止改善等の美容効果があることが確認できた。 As shown in Table 1, acetic acid ceramide has superior anti-wrinkle activity than plant-type sugar ceramide, and from this, acetic acid ceramide has a cosmetic effect such as moisturizing, preventing rough skin, and preventing wrinkle by ingestion. It was confirmed that there is.
(実施例2)
<ヒト皮膚器官培養を用いた酢酸菌セラミド体内吸収分解物の抗シワ活性>
経口摂取したセラミドの一部は分解され吸収され作用すると考えられる。
(Example 2)
<Anti-wrinkle activity of absorptive ceramide in human skin organ culture>
Part of ceramide taken orally is considered to be decomposed and absorbed.
試験に供したスフィンゴシン(D−erythro−sphingoside: Avanti社製)はヒト型セラミドならびにヒト型糖セラミドの脂肪酸ならびに糖部分が分解遊離したスフィンゴイド塩基部分の物質である。 Sphingosine (D-erythro-sphingoside: manufactured by Avanti) used for the test is a substance of the sphingoid base part in which the fatty acid and sugar part of the human type ceramide and human type sugar ceramide are decomposed and released.
また、スフィンガニン(D−erythro−sphingosine: Avanti社製)は酢酸菌セラミドの脂肪酸部分が分解遊離したスフィンゴイド塩基部分の物質であり、共にヒト生体内でその存在が確認されている。 Moreover, sphinganine (D-erythro-sphingosine: manufactured by Avanti) is a substance of a sphingoid base part in which the fatty acid part of acetic acid bacteria ceramide is decomposed and released, both of which have been confirmed in vivo.
また、植物糖セラミドの脂肪酸ならびに糖部分が分解遊離したスフィンゴイド塩基部分の主要な物質はスフィンガジエンであり、小腸上皮細胞のモデル培養細胞であるCaco−2での吸収効率試験で、スフィンガジエンはスフィンゴシンよりも吸収効率が著しく劣ることが示されている(例えば、「ジャーナル・オブ・ニュートリション(Journal of Nutrition)」、133巻、p.2777〜2782、2003年参照)。 The main substance of the sphingoid base moiety in which the fatty acid and sugar moiety of the plant sugar ceramide is decomposed and released is sphingadiene. In the absorption efficiency test in Caco-2, which is a model culture cell of small intestinal epithelial cells, Diene has been shown to be significantly less efficient in absorption than sphingosine (see, eg, “Journal of Nutrition”, 133, p. 2777-2782, 2003).
以上のことから、ヒト型糖セラミドならびにヒト型セラミドの分解物であるスフィンゴシン、酢酸菌セラミドの分解物であるスフィンガニンの抗シワ活性について比較評価した。 Based on the above, the anti-wrinkle activity of human-type sugar ceramide, sphingosine, which is a degradation product of human-type ceramide, and sphinganine, which is a degradation product of acetic acid ceramide, was comparatively evaluated.
評価系は実施例1で用いたものと同様の抗シワ活性評価系を同条件で使用した。
以上の結果を表2に示す。
The evaluation system used was the same anti-wrinkle activity evaluation system used in Example 1 under the same conditions.
The results are shown in Table 2.
(表2)
――――――――――――――――――――――――――――――――――――――――
名称 評価 評価の根拠
――――――――――――――――――――――――――――――――――――――――
スフィンガニン EXCELLENT 皮膚表面も表面レプリカもシワが殆ど存在しない。
スフインゴシン GOOD 皮膚表面は皮丘が幾つか見られるが、表面レプリカでは広幅の皮溝はない。
無投与区 POOR 随所に広幅の陥没部が認められる。
――――――――――――――――――――――――――――――――――――――――
(Table 2)
――――――――――――――――――――――――――――――――――――――――
Name Evaluation Basis for evaluation ――――――――――――――――――――――――――――――――――――――――
Sphinganine EXCELLENT There are almost no wrinkles on the skin surface or surface replica.
Sphingosine GOOD The skin surface has several skin hills, but the surface replica does not have a wide skin groove.
Non-administration zone POOR Wide depressions are observed everywhere.
――――――――――――――――――――――――――――――――――――――――
表2の結果から、スフィンガニンがスフィンゴシンよりも優れた抗シワ活性が確認できたことより、経口投与によって一部分解された場合であっても酢酸菌セラミドは高い抗シワ活性を示すことが期待できる。このことより酢酸菌セラミドは経口摂取により保湿、肌荒れ防止改善、シワ防止改善等の美容効果があることが期待できる。 From the results of Table 2, it can be expected that acetic acid ceramide exhibits high anti-wrinkle activity even when it is partially decomposed by oral administration, since sphinganine was confirmed to have superior anti-wrinkle activity than sphingosine. From this fact, acetic acid ceramide can be expected to have cosmetic effects such as moisturizing, preventing rough skin, and preventing wrinkles by ingestion.
(実施例3)
<アトピー性皮膚炎モデルマウスを用いた酢酸菌セラミドの肌機能改善効果>
アトピー性皮膚炎のモデルマウスとして4週齢のNC/Nga Tnd Crj系オスマウスを使用した。NC/Nga Tnd Crj系オスマウスは、SPF飼育環境下では肉眼的所見として異常を呈さないが、空気中の微生物制御を行っていない通常飼育環境下では、肌荒れ、保湿能力の低下等の強い皮膚炎症状を自然発症するマウスである。
(Example 3)
<Skin function improvement effect of acetic acid ceramide using atopic dermatitis model mouse>
As a model mouse for atopic dermatitis, 4-week-old NC / Nga Tnd Crj male mice were used. NC / Nga Tnd Crj male mice do not exhibit abnormalities as macroscopic findings in the SPF breeding environment, but strong dermatitis such as rough skin and reduced moisturizing ability in the normal breeding environment in which airborne microorganisms are not controlled It is a mouse that spontaneously develops symptoms.
酢酸菌セラミドとして、2−Hydroxy−C16−Dihydroceramide(MATREYA社製)を使用した。 2-Hydroxy-C16-Dihydroceramide (manufactured by MATREA) was used as the acetic acid ceramide.
群は無投与対照区ならびに酢酸菌セラミド投与区の2群を設定し、それぞれ10匹を1群とした。無投与対照区はAIN93G(オリエンタル酵母工業社製)を自由摂取させた。酢酸菌セラミド投与区は、AIN93Gに酢酸菌セラミドを0.15%外割添加した飼料を自由摂取させた。 Two groups, a non-administration control group and an acetic acid ceramide ceramide administration group, were set, and 10 animals each were one group. In the non-administration control group, AIN93G (manufactured by Oriental Yeast Co., Ltd.) was freely ingested. The acetic acid bacteria ceramide administration group was allowed to freely ingest a feed in which 0.15% of acetic acid bacteria ceramide was added to AIN93G.
試験開始22日後に毛刈りしたマウス腹部および足蹠5w/v%PiCl溶液を150μl/匹になるように塗布し感作した。 22 days after the start of the test, a mouse abdomen shaved and footpad 5 w / v% PiCl solution was applied at 150 μl / animal and sensitized.
感作後4日目から毛刈した背部および左右の耳(内側両側)に0.8w/v%PiCl溶液を150μl/匹になるように塗布し誘発した。投与は67日間行い、1回/週あたりで自由飲水量を測定し、一日あたりの摂水量を算出した。結果を図2に示した。 From the 4th day after sensitization, the hair was shaved and the left and right ears (both sides) were applied with a 0.8 w / v% PiCl solution at 150 μl / animal to induce. Administration was carried out for 67 days, and the amount of free drinking was measured once per week, and the amount of water intake per day was calculated. The results are shown in FIG.
図2の結果から、飼育週齢の増加に従い対照区ならびに酢酸菌セラミド投与区ともに摂水量の増加傾向にあるが、対照区では酢酸菌セラミド投与区に比較して摂水量の増加が多く、皮膚から蒸散した水分を補給するために大量の水分摂取が必要であると考えられる。このことより明らかに経口摂取によって酢酸菌セラミドが保湿、肌荒れ防止改善、シワ防止改善等の美容効果を有するといえる。 From the results of FIG. 2, the control group and the acetic acid ceramide administration group tend to increase the water intake as the breeding age increases. However, the control group has a greater increase in water intake than the acetic acid ceramide administration group, and the skin It is considered that a large amount of water intake is necessary to replenish the transpiration of water. From this, it can be said that acetic acid ceramide has cosmetic effects such as moisturizing, preventing rough skin, and preventing wrinkle by oral ingestion.
(実施例4)
<錠剤の調製>
酢酸菌としてAcetobacter aceti NBRC 14818を用い、その酢酸発酵液10キロリッターを高速遠心機器(8000rpm、20分)で集菌し、湿菌体10Kgを得た。得られた湿菌体10Kgを蒸留水にて洗浄後に大型凍結乾燥機で凍結減圧乾固し、乾燥菌体1.8Kgを得た。
Example 4
<Preparation of tablets>
Acetobacter acetic NBRC 14818 was used as an acetic acid bacterium, and 10 kiloliters of the acetic acid fermentation broth was collected with a high-speed centrifuge (8000 rpm, 20 minutes) to obtain 10 kg of wet cells. 10 kg of the obtained wet microbial cells were washed with distilled water and then freeze-dried under reduced pressure using a large lyophilizer to obtain 1.8 kg of dried microbial cells.
得られた乾燥菌体1Kgをエタノール10リッターとともにソックスレー抽出器に仕込み、20時間加熱還流した。得られた抽出液を減圧乾固し、5リットルのアセトンに溶解した。沈殿物をろ過で除去し、ろ液をロータリーエバポレーターで蒸発乾固し、淡黄褐色の酢酸菌セラミド1.5gを得た。 1 kg of the obtained dried cells were charged into a Soxhlet extractor together with 10 liters of ethanol and heated to reflux for 20 hours. The obtained extract was dried under reduced pressure and dissolved in 5 liters of acetone. The precipitate was removed by filtration, and the filtrate was evaporated to dryness with a rotary evaporator to obtain 1.5 g of light yellowish brown acetic acid ceramide.
得られた酢酸菌セラミド1g(0.7重量%)、結晶セルロース35g(26.9重量%)、乾燥コーンスターチ67g(51.5重量%)、乳糖22g(16.9重量%)、ステアリン酸カルシウム2g(1.5重量%)、および結合剤としてポリビニルピロリドン3g(2.3重量%)を加え、混合粉末化した後に、ゼラチン硬カプセルに充填した。 Acetic acid bacteria ceramide 1 g (0.7 wt%), crystalline cellulose 35 g (26.9 wt%), dried corn starch 67 g (51.5 wt%), lactose 22 g (16.9 wt%), calcium stearate 2 g (1.5% by weight) and 3 g (2.3% by weight) of polyvinylpyrrolidone as a binder were added, mixed powdered, and then filled into hard gelatin capsules.
このようにして調製された錠剤は、肌機能改善組成物として、有用に経口摂取可能であることが充分に期待される。 The tablet thus prepared is sufficiently expected to be usefully orally ingested as a skin function improving composition.
(実施例5)
<ゼリーの製造>
酢酸菌としてAcetobacter aceti NBRC 14818を用い、その酢酸発酵液10キロリッターを高速遠心機器(8000rpm、20分)で集菌し、湿菌体10Kgを得た。得られた湿菌体10Kgを等量の蒸留水に分散させた。分散させた20kgの酢酸菌分散液を高圧ホモジナイザー(20000psi)に3回通過させ細胞破壊処理を施した後に、大型凍結乾燥機で凍結減圧乾固し、乾燥菌体粉末1.5Kgを得た。
(Example 5)
<Manufacture of jelly>
Acetobacter acetic NBRC 14818 was used as an acetic acid bacterium, and 10 kiloliters of the acetic acid fermentation broth was collected with a high-speed centrifuge (8000 rpm, 20 minutes) to obtain 10 kg of wet cells. The obtained wet bacterial cells (10 kg) were dispersed in an equal amount of distilled water. The dispersed 20 kg of acetic acid bacteria dispersion was passed through a high-pressure homogenizer (20000 psi) three times and subjected to cell destruction treatment, and then freeze-dried under reduced pressure using a large freeze dryer to obtain 1.5 kg of dried cell powder.
得られた乾燥菌体粉末8g(0.8重量%)、砂糖250g(25重量%)、カラギーナン1.6g(0.16重量%)、ローカストビーンガム0.8g(0.08重量%)、キサンタンガム0.8g(0.08重量%)を混合均一化し、粉体混合物を得た。鍋に300gの水を計量し、黒糖30g(3.0重量%)を溶解し、さらに還元水あめ150g(15重量%)を混合し、先に得た粉体混合物をダマができないように攪拌しながら、更に混合した。それらを均一に攪拌し、残りの水258.8gを加え、加温した。溶液温度が85℃10分間加熱溶解後、流水で冷却し酢酸菌体含有ゼリー食品を得た。 8 g (0.8 wt%) of the obtained dry cell powder, 250 g (25 wt%) sugar, 1.6 g (0.16 wt%) carrageenan, 0.8 g (0.08 wt%) locust bean gum, Xanthan gum 0.8 g (0.08 wt%) was mixed and homogenized to obtain a powder mixture. Weigh 300 g of water in a pan, dissolve 30 g (3.0% by weight) of brown sugar, mix 150 g (15% by weight) of reduced water candy, and stir the powder mixture obtained previously so that it does not become lumpy. Further mixing was performed. They were stirred uniformly and the remaining 258.8 g of water was added and warmed. The solution was heated and dissolved at 85 ° C. for 10 minutes, and then cooled with running water to obtain acetic acid bacterium-containing jelly food.
このようにして調製されたゼリーは、肌機能改善用組成物として、有効に経口摂取可能であることが期待できる。 The jelly thus prepared can be expected to be effectively orally ingested as a skin function improving composition.
(実施例6)
<飲料の製造>
酢酸菌としてAcetobacter aceti NBRC 14818を用い、その酢酸発酵液10キロリッターを高速遠心機器(8000rpm、20分)で集菌し、湿菌体10Kgを得た。得られた湿菌体10Kgを食酢100リッターに分散させた。分散させた酢酸菌分散液を高圧ホモジナイザー(20000psi)に3回通過させ細胞破壊処理を施した。その溶液を500ml容の瓶に分注し、75℃まで加温により殺菌し酢酸菌体含有食酢を得た。
(Example 6)
<Manufacture of beverages>
Acetobacter acetic NBRC 14818 was used as an acetic acid bacterium, and 10 kiloliters of the acetic acid fermentation broth was collected with a high-speed centrifuge (8000 rpm, 20 minutes) to obtain 10 kg of wet cells. 10 kg of the obtained wet bacterial cells were dispersed in 100 liters of vinegar. The dispersed acetic acid bacteria dispersion was passed through a high-pressure homogenizer (20000 psi) three times for cell destruction treatment. The solution was dispensed into 500 ml bottles and sterilized by heating to 75 ° C. to obtain vinegar containing acetic acid bacteria.
このようにして調製された飲料は、肌機能改善用組成物として、有効に経口摂取可能であることが期待できる。 It can be expected that the beverage thus prepared can be effectively taken orally as a composition for improving skin function.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005013382A JP4223483B2 (en) | 2005-01-20 | 2005-01-20 | Composition for improving skin function comprising acetic acid ceramide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005013382A JP4223483B2 (en) | 2005-01-20 | 2005-01-20 | Composition for improving skin function comprising acetic acid ceramide |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007285801A Division JP2008056695A (en) | 2007-11-02 | 2007-11-02 | Composition for ameliorating skin function, containing ceramide from acetobacter |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006199626A true JP2006199626A (en) | 2006-08-03 |
JP4223483B2 JP4223483B2 (en) | 2009-02-12 |
Family
ID=36957943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005013382A Active JP4223483B2 (en) | 2005-01-20 | 2005-01-20 | Composition for improving skin function comprising acetic acid ceramide |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4223483B2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006199624A (en) * | 2005-01-20 | 2006-08-03 | Mitsukan Group Honsha:Kk | Acetobacter-containing in vivo antioxidative composition |
JP2007070342A (en) * | 2005-08-09 | 2007-03-22 | Mitsukan Group Honsha:Kk | Composition for ameliorating cerebral function |
WO2008087704A1 (en) * | 2007-01-16 | 2008-07-24 | Mizkan Group Corporation | Composition for improving brain function |
WO2008087705A1 (en) * | 2007-01-16 | 2008-07-24 | Mizkan Group Corporation | Composition for inhibiting muscle damage |
JP2017178842A (en) * | 2016-03-30 | 2017-10-05 | 小林製薬株式会社 | Dermal fibroblast activator and use therefor |
JP7304997B1 (en) | 2022-03-30 | 2023-07-07 | キユーピー株式会社 | Oil and fat composition, method for producing oil and fat composition, flavor enhancer, and food |
-
2005
- 2005-01-20 JP JP2005013382A patent/JP4223483B2/en active Active
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006199624A (en) * | 2005-01-20 | 2006-08-03 | Mitsukan Group Honsha:Kk | Acetobacter-containing in vivo antioxidative composition |
JP2007070342A (en) * | 2005-08-09 | 2007-03-22 | Mitsukan Group Honsha:Kk | Composition for ameliorating cerebral function |
WO2008087704A1 (en) * | 2007-01-16 | 2008-07-24 | Mizkan Group Corporation | Composition for improving brain function |
WO2008087705A1 (en) * | 2007-01-16 | 2008-07-24 | Mizkan Group Corporation | Composition for inhibiting muscle damage |
JP2017178842A (en) * | 2016-03-30 | 2017-10-05 | 小林製薬株式会社 | Dermal fibroblast activator and use therefor |
JP7304997B1 (en) | 2022-03-30 | 2023-07-07 | キユーピー株式会社 | Oil and fat composition, method for producing oil and fat composition, flavor enhancer, and food |
WO2023190985A1 (en) * | 2022-03-30 | 2023-10-05 | キユーピー株式会社 | Oil-and-fat composition, production method for oil-and-fat composition, flavor enhancer, and food product |
Also Published As
Publication number | Publication date |
---|---|
JP4223483B2 (en) | 2009-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090257965A1 (en) | Abnormal protein removing composition | |
TWI436774B (en) | Skin enhancers and their use | |
JP4163631B2 (en) | Fermentation composition of spicy varieties of chili pepper and its use | |
JP5822423B2 (en) | Skin fibroblast proliferation promoter, transglutaminase-1 production promoter, elastase activity inhibitor, MMP-1 activity inhibitor, estrogen-like agent, type I collagen production promoter, and recovery agent from UV-B damage | |
US6896896B2 (en) | Physiologically functional foods or cosmetics containing sphingoglycolipids and processes for their production | |
JP4223483B2 (en) | Composition for improving skin function comprising acetic acid ceramide | |
JP6482930B2 (en) | Skin cosmetics and foods and drinks | |
JP2001316240A (en) | Collagen production promoter, estrogenic agent, skin cosmetic and food for beauty | |
KR20100015326A (en) | Melanogenesis inhibitory composition | |
KR102358623B1 (en) | Food composition for improving skin condition comprising collagen peptide | |
JP2008308505A (en) | Composition for removing abnormal protein | |
JP2008013531A (en) | Collagen production promoter and food and beverage for beauty containing the same | |
JP2008056695A (en) | Composition for ameliorating skin function, containing ceramide from acetobacter | |
JP3827581B2 (en) | Skin cosmetics and beauty food and drink | |
JP2006321730A (en) | Antioxidant, antiaging agent, skin cosmetics, and food or drink | |
JP2003137801A (en) | Collagen production promoter, collagenase inhibitor, fibroblast cell-propagating agent, skin cosmetic material and food or beverage for cosmetic use | |
KR102511701B1 (en) | Functional collagen composition using collagen amino acid derived from Aurea Helianthus | |
KR102351730B1 (en) | Food comprising fermented Tremella fuciformis and Method for preparing the same | |
JP2005029483A (en) | Active oxygen-eliminating agent, and cosmetic and food and drink | |
JP2007269659A (en) | Antioxidant composition | |
JP2006008571A (en) | Moisturizer, antioxidant, antiaging agent, skin cosmetic and beauty drink and food | |
JP2004331543A (en) | Fibroblast growth-promoting agent and skin cosmetic and beauty food or drink | |
JP6741401B2 (en) | Method for producing ceramide-containing composition | |
JP6158147B2 (en) | Whitening agent and internal or external composition containing the same | |
JP4077002B2 (en) | Melanin production inhibiting composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070713 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20070717 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070904 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071102 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20071102 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080321 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20080410 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080324 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080610 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080807 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080918 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20081021 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20081118 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081119 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4223483 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111128 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141128 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |